Paganelli, Franck

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Role of endogenous adenosine as a modulator of syncope induced during tilt testing

Saadjian, A. Y., Lévy, S., Franceschi, F., Zouher, I., Paganelli, F., & Guieu, R. P. (2002) · Circulation

Cardiovascular Syncope and Autonomic DisordersAdenosine and Purinergic Signaling

Cited by 91

Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes

Bonello, L., Laine, M., Puymirat, E., Lemesle, G., Thuny, F., Paganelli, F., Michelet, P., Roch, A., Kerbaul, F., & Boyer, L. (2016) · JACC: Cardiovascular Interventions

Acute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Cited by 81